ArticleVeterinary research2025
Targeting STEC-induced edema disease in weaned piglets: prophylactic oral phage P-GXEC-L2P5 attenuates bacterial colonization, toxin production, and endothelial damage.
Article in Veterinary research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Edema disease (ED), a fatal disease in weaned piglets, is caused by Shiga toxin-producing Escherichia coli (STEC). The increasing emergence of antibiotic-resistant E. coli strains has necessitated the exploration of alternatives such as bacteriophage therapy. Using a porcine model, this study evaluated the prophylactic effect of bacteriophage P-GXEC-L2P5 administered by oral gavage against ED. The novel phage P-GXEC-L2P5 was isolated using a multidrug-resistant (MDR) STEC strain GXEC-STL2 as the host. P-GXEC-L2P5 was identified as a member of Caudoviricetes, Dhillonvirus, with an 88,607 base pair (bp) genome, and it possessed a short latent period (10 min), moderate pH stability (5-10), and appropriate thermal tolerance (4-60 ℃). Piglets pretreated with P-GXEC-L2P5 showed no apparent clinical signs (e.g., eyelid edema or neurological symptoms) after challenge with GXEC-STL2. B-scan ultrasound revealed no significant hydronephrosis. Necropsy showed only mild intestinal congestion, with no other gross pathological lesions noted. Histopathology demonstrated no significant differences in features compared with noninfected controls. Phage treatment significantly reduced fecal STEC shedding (P < 0.05) and significantly decreased Stx2e concentrations in serum, cerebral cortex, kidney, and small intestine (P < 0.01). The messenger RNA (mRNA) expression of Gb4 (Stx2e receptor) was significantly lower in these tissues (P < 0.05). Concurrently, vascular endothelial cells exhibited increased FITC-labeled wheat germ agglutinin (FITC-WGA) fluorescence intensity and increased mRNA expression of endothelial integrity factors (connexin43, vinculin, and zonula occludens-1; P < 0.05). In addition, phage treatment preserved jejunal microbiota diversity and abundance. In conclusion, P-GXEC-L2P5 effectively prevented STEC-induced ED by reducing STEC load and Stx2e levels, while mitigating increased vascular permeability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.